Azitra Inc (AZTR)
AZTR trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/0001701478-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AZTR on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2023 |
| SEC CIK | 0001701478 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$11.0M |
| Operating income | -$11.0M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $2.1M |
| Total assets | $5.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions and events create substantial doubt about the ability of the Company to continue as a going concern for twelve months from the date that the financial statements are available to be issued." | 10-Q 2026-11-12 |
| Cash and burn | $3.8M cash; operating cash flow -$2.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 6,060,435 (2026-11-12); 10,204,938 a year earlier; 12,097,643 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-2000 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 3; latest 1-for-10 on 2026-10-26 | Source 2026-10-26 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-09-28 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-03-13 |
| Auditor | Grassi & Co., CPAs, P.C., Jericho, New York, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$2.9M | -$2.9M | $3.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$3.3M | -$3.3M | $6.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$3.9M | -$2.5M | $10.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | $0 | -$2.2M | -$2.9M | $2.1M | No debt tags | $0 | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $0 | -$2.8M | -$2.4M | $1.4M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$2.9M | -$2.8M | $1.0M | No debt tags | Needs four quarters | 10-Q 2025-08-11 |
| Q1 2025 2025-03-31 | Not filed | -$3.1M | -$3.1M | $3.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | $0 | -$2.4M | -$2.6M | $4.6M | No debt tags | $8K | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-28 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-06-04 |
Source: SEC EDGAR submissions feed, 242 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.1% |
| 1 month | -15.6% |
| 3 months | -56.6% |
| Year to date | -77.1% |
| 1 year | -82.4% |
| From 52-week high | -84.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XTLB | XTL Biopharmaceuticals Ltd. | $1.54 | -3.75% | $3.8M |
| GELS | Gelteq Limited | $0.3589 | -5.63% | $3.8M |
| IMNN | Imunon Inc. | $0.5940 | -5.56% | $3.9M |
| TRAW | Traws Pharma Inc. | $0.2600 | +3.59% | $4.0M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| BGMS | Bio Green Med Solution Inc. | $0.6502 | +1.55% | $4.3M |
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier